



## Xencor to Present at Upcoming Investor Conferences

May 8, 2019

MONROVIA, Calif.--(BUSINESS WIRE)--May 8, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will present at two upcoming conferences:

- **Bank of America Merrill Lynch 2019 Health Care Conference**

**Date:** Wednesday, May 15, 2019

**Location:** Las Vegas, NV

**Presentation Time:** 4:20 p.m. PT

- **Berenberg Conference USA 2019**

**Date:** Wednesday, May 22, 2019

**Location:** Tarrytown, NY

**Presentation Time:** 9:45 a.m. ET

A live webcast of the Bank of America Merrill Lynch conference will be available under "Events & Presentations" in the Investors section of the Company's website located at <https://investors.xencor.com/events.cfm>. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 90 days following the event.

### About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases. Currently, 13 candidates engineered with Xencor's XmAb<sup>®</sup> technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit [www.xencor.com](http://www.xencor.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190508005748/en/>

Source: Xencor, Inc.

Charles Liles  
626-737-8118  
[cliles@xencor.com](mailto:cliles@xencor.com)

Media Contact  
Jason I. Spark  
Canale Communications  
619-849-6005  
[jason@canalecomm.com](mailto:jason@canalecomm.com)